Exagen (XGN)
(Delayed Data from NSDQ)
$2.40 USD
+0.36 (17.65%)
Updated Aug 5, 2024 04:00 PM ET
After-Market: $2.41 +0.01 (0.42%) 4:40 PM ET
3-Hold of 5 3
C Value B Growth C Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
XGN 2.40 +0.36(17.65%)
Will XGN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for XGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for XGN
Exagen Inc. (XGN) Reports Q2 Loss, Tops Revenue Estimates
Why Fast-paced Mover Exagen (XGN) Is a Great Choice for Value Investors
XGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Time to Play 5 Top-Ranked Stocks With Rising P/E?
Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates
Quanterix Corporation (QTRX) Reports Q1 Loss, Tops Revenue Estimates
Other News for XGN
XGN Stock Earnings: Exagen Beats EPS, Beats Revenue for Q2 2024
Exagen, Inc. (XGN) Q2 2024 Earnings Call Transcript
Exagen GAAP EPS of $0.16 beats by $0.50, revenue of $15.1M beats by $1.97M
Exagen Inc. Reports Strong Second Quarter 2024 Results: Raises Guidance due to Record Performance
Exagen reports Q2 EPS (16c), consensus (34c)